Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals — Merger or Acquisition (November 2022)

17 slides from Opiant Pharmaceuticals's merger presentation, Nov 15, 2022

  1. Slide 1: Indivior To Acquire Opiant Pharmaceuticals

    Indivior To Acquire Opiant Pharmaceuticals Acquisition Strengthens and Extends Indivior’s Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to Confront Illicit Synthetic Opioids Like

  2. Slide 2: Indivior

    se SVE INDIVIOR

  3. Slide 3: Forward-looking statements

    Forward-looking statements

  4. Slide 4: ‘Remand om sin pk aha td eed

    ‘Remand om sin pk aha td eed Steen nr sas es nn ue wes ees eo moe oe Sop ce este ee yar yon mee SUSicseranane atc atteminne ache oy sana opse tases macros ace sab saan SLE ae rare ec py mena nga aenomor

  5. Slide 5: Opiant Pharmaceuticals

    piant Pharmaceuticals

  6. Slide 6: Compelling strategic & financial rationale

    Compelling strategic & financial rationale Sgn Fann aoe ae G ors ue al of 30m 200) Esrircieserr ena dial G “aaacon anetk © sms @ mazar

  7. Slide 7: Leading addiction treatment and science platform upon closing

    leading a ion treatment and science platform upon closing in na a sy

  8. Slide 8: OPNT003 addresses the current wave of US opioid overdose driven by synthetics

    OPNTOO3 addresses the current wave of US opioid overdose being driven by synthetics 12 Mtn oper on Nant tong omine Day ge Der Smut ite

  9. Slide 9: Synthetic opioids are challenging current treatment options

    Synthetic opioids are challenging current treatment options Most of the crews tetoanenas Cera ene 2° having to use perenne ae eee a BESO NVARCAN® (naloxone) per patient just t them breathing again”

  10. Slide 10: Scientific evidence confirms OPNT003's potential to improve and sustain reversal of opioid overdose

    Scientific evidence confirms OPNTO03’s potential to improve and sustain reversal of opioid overdose

  11. Slide 11: Fast-Track designation expected 2022; expected approval Q3 2023

    ‘ast-Track” designation expected 04 2022; expected approval Q3 2023, o-¢ oo - eee ee slenomon

  12. Slide 12: OPNT003 is complementary to SUBLOCADE and Patient Recovery

    ‘OPNTOO3 is complementary to SUBLOCADE® and Patient Recovery fom) (on es =) eg) qr ecrntntome etc (cn) NY enone

  13. Slide 13: OPNT003 is complementary to SUBLOCADE and Patient Recovery

    ‘OPNTOO3 is complementary to SUBLOCADE® and Patient Recovery fom) (on es =) eg) qr ecrntntome etc (cn) NY enone

  14. Slide 14: OPNT002 - Attractive opportunity as an as-needed nasal spray

    OPNT0O2 — Attractive ‘opportunity with the potential to become “as needed” nasal spray when patient anticipates drinking or craving alcohol ‘Wnasman gsm chan ong enone

  15. Slide 15: Transaction summary

    Transaction summary* = ome SSUES args hore cerernrentnonenseaernememnyceame “Son ee nen ate a RO semontor .

  16. Slide 16: Narcan Owner Opiant to Be Acquired by Indivior for $145 Million

    Narcan Owner Opiant to Be Acquired by Indivior for $145 Million The combination of addiction-drug makers could tap into billions of dollars in settlement and federal funds aimed at expanding access to treatment MARK CROSSLEY WELCOMING VIDEO SCRIPT My name is Mark Crossley, and I’d like to personally

  17. Slide 17: Indivior

    vW NA AS INDIVIOR

Opiant Pharmaceuticals — Merger or Acquisition (November 2022) on 6ix